BMYMP News and Press, Bristol-Myers Squibb $2Pr From 07/04/22

The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names. It's clear (to us) that AUPH should be on the ...

The VanEck Morningstar Wide Moat ETF ("MOAT") invests in U.S. companies that possess wide economic moats per Morningstar's methodology. The ETF was not immune to the market's retreat in Q2, but still held its own against major indexes. A look at the discounts to fair value calcula...

We conclude our roundtable series with Biotech and Healthcare coverage. Seven of our Marketplace contributors give their analysis and share one top idea. Look for more roundtables and analysis this summer from our community of 180+ Marketpalce services. ~ By Tim Murphy, Ma...

Bristol-Myers Squibb's EBITDA margin is 47.2% at the end of Q1 2022, which is one of the largest values in the pharmaceutical industry. Due to the loss of exclusivity, Revlimid's sales were $2,797 million in Q1 2022, down 16% from Q1 2021. Global sales of Opdivo were $1,923 millio...

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend Champion, Contender, An...

Bristol-Myers Squibb Company (BMY) Goldman Sachs 43rd Annual Global Healthcare Conference June 15, 2022 12:20 ET CorporateParticipants Adam Lenkowsky - Senior Vice President and General Manager, U.S. Commercialization ConferenceCall Participants Chris Shibutani - Goldman Sachs Presentation Ch...

Market timing can be a very attractive and tempting strategy in theory, particularly in challenging markets like today but can be difficult to achieve in real-time. “Factor momentum” is using the recent price action of a given factor (value, growth, quality, etc.) to pre...

Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...

Bristol-Myers Squibb Company (BMY) Bernstein 38th Annual Strategic Decisions Conference Call June 2, 2022 08:00 ET Company Participants Giovanni Caforio - Chief Executive Officer Samit Hirawat - Chief Medical Officer Conference Call Participants Wimal Kapadia - Bernstein Presentation Wimal Ka...

The Carillon Family of Funds spans a range of investment objectives and asset classes designed for long-term investors. Q1 2022 was marred by tragedy on a global scale and investors encountered three months of volatile trading induced by persistently high inflation, rising rates, and ...